ALKS Stock Alkermes plc - Complete Overview
Nasdaq / Pharmaceutical Products / Healthcare / ALKS Stock
|Avg Daily Volume||1.27M|
ALKERMES PLC (ALKS) OVERVIEW
ALKS stock is a pharmaceutical products company traded on Nasdaq. It is valued at 10.5B US dollars. There are 156.14M shares outstanding which Alkermes plc issued to investors. Volatility of the stock is MEDIUM, and the daily volume is 44.39% stock on average. It brought investors a total return of -18.65% over the last 12 months. Alkermes plc stock is relatively cheap. It's P/E ratio is below the market average.
Johnson & Johnson's First-Quarter 2018 Earnings Review
We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.
Is It Time to Give Up on Alkermes?
It feels like we've been here before.
Alkermes's stock soars after FDA accepts NDA review, 2 weeks after refusing
Shares of Alkermes PLC soared 21% in premarket trade Monday, after the biopharmaceutical company said the Food and Drug Administration accepted for review the company's new drug application (NDA) for its treatment of major depressive disorder (MDD). The acceptance comes after the FDA had initially issued a "refusal to file" letter for the MDD treatment, ALKS 5461, on March 30. The stock had plunged 22% on April 2, when the news of the letter was released. Alkermes said the rescission of the refusal letter followed "productive interactions" with the FDA, in which it "clarified" certain aspects of the NDA submission, without any additional data or analyses submitted. Alkermes's stock had tumbled 22.3% year to date through Friday, while the SPDR S&P Biotech ETF had gained 5.6% and the S&P 500 had slipped 0.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Alkermes Has Some Decisions to Make
Following a recent setback, management has a tougher road ahead.
Alkermes Receives Refusal To File Letter From The FDA, Is There Any Hope?
Alkermes receives refusal to file letter from the FDA putting a bearish outlook for the company for its ALKS-5461 treatment.The company achieved the primary endpoint in only one of the three phase 3 s
Alkermes' Bad News Could Be Good News for Johnson & Johnson
A stumble at Alkermes could mean one less competitor for a new drug making its way through J&J's pipeline.
|Price to Earnings||0.00||32.53||28.84||45.62|
|Price to Book Value||8.73||6.82||6.57||7.00|
|Price to Sales||11.63||3.95||3.69||5.00|
|Return on Equity||0.00%||12.78%||11.13%||17.71%|
|Return on Assets||0.00%||6.01%||4.94%||8.04%|